ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GALT Galectin Therapeutics Inc

3.06
0.22 (7.75%)
16 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Galectin Therapeutics Inc NASDAQ:GALT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.22 7.75% 3.06 2.80 3.35 3.12 2.78 2.78 136,434 01:00:00

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. & Its Board of ...

10/09/2014 10:33pm

Business Wire


Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Galectin Therapeutics Charts.

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of investors who purchased Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NasdaqCM:GALT) securities between January 6, 2014 and July 28, 2014.

For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt.

The complaint alleges that during the Class Period, the Company violated federal securities laws by issuing false and misleading statements regarding its business and prospect. As a result of these statements, Galectin stock traded at artificially inflated prices.

On July 28, 2014, an article featured on TheStreet.com noted that Galectin hired a stock promotions firm known as Emerging Growth Corp. to tout its stock. The article further notes that Emerging Growth “describes itself as an investor relations and marketing company, but that it’s just a shiny façade on what is really an ugly penny-stock promotions scheme.” The following day, Galectin reported disappointing results regarding its phase 1 experimental drug trial for GR-MD-02.

If you suffered a loss in Galectin you have until September 29, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/galectin-therapeutics-galt.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLPJoseph Levi, Esq.Eduard Korsinsky, Esq.Tel: 212-363-7500Toll Free: 877-363-5972Fax: 866-367-6510www.zlk.com

1 Year Galectin Therapeutics Chart

1 Year Galectin Therapeutics Chart

1 Month Galectin Therapeutics Chart

1 Month Galectin Therapeutics Chart

Your Recent History